J
Judo Bio
Biotech & Life Sciences · Cambridge, United States · Founded 2021
Innovative oligonucleotide medicines targeting kidney diseases through proprietary siRNA delivery technology MoreLess
Judo Bio is at the forefront of developing oligonucleotide medicines specifically targeting the kidney, an organ traditionally challenging for genetic treatments. The company operates within the biotechnology sector, focusing on creating RNA-based therapies for both systemic and renal diseases. Judo Bio's unique STRIKE platform leverages a natural mechanism to deliver siRNA, a type of genetic material, directly to kidney cells. This approach allows for the silencing of disease-causing genes by targeting specific solute carrier proteins, which are crucial for kidney function. The business model revolves around the development and commercialization of these proprietary therapies, aiming to partner with pharmaceutical companies for distribution and further development. Revenue is generated through licensing agreements, collaborations, and potential future sales of approved therapies. Judo Bio primarily serves healthcare providers and pharmaceutical companies looking for advanced treatments for kidney-related conditions. The company is positioned in a niche market with significant growth potential due to the increasing demand for innovative genetic therapies. Keywords: oligonucleotide, siRNA, kidney, RNA medicines, gene silencing, STRIKE platform, systemic diseases, renal diseases, megalin STRIKERs, biotechnology.
Company overview
Judo Bio company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2021
- Headquarters
- Cambridge, United States
- Employees
- 32
- Open positions
- None listed
- Dealroom signal
- 60.7
Valuation & funding
Judo Bio funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Oct 2024 | $75M | $300M | Atlas Venture · The Chernin Group · Alexandria Venture Investments · Euclidean Capital | ↗ |
| SEEDOther financing | Apr 2024 | $25M | $100M | The Column Group | ↗ |
Growth signals
Judo Bio website traffic
Latest recorded traffic for Judo Bio is 2.5K monthly website visits, down 10.7% over the last three months.
Hiring
Open positions at Judo Bio
Current openings linked to this company in Dealroom.
Comparisons
Judo Bio compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Judo Bio's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Judo Bio has talent and traffic
team presence
In the news
Latest news about Judo Bio
Recent press, funding announcements, and product moves mentioning Judo Bio — open to read from the original sources.
Market sentiment
What the market is saying about Judo Bio
An AI-synthesized read of the highest-engagement posts about Judo Bio on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Judo Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.